Purpose In 2015, we published a study on a small series of patients with hepatocellular carcinoma (HCC) treated chronically with metformin for type II diabetes mellitus (DM2) who showed a poorer response to sorafenib. The aim of the present study was to validate the prognostic significance of metformin in HCC patients treated with sorafenib, providing a biological rationale for the mechanism of resistance to sorafenib in patients on chronic metformin therapy, and to clarify the role of sirtuin-3 (SIRT-3), a protein involved in metabolic diseases and acknowledged as a tumour suppressor in HCC, in this resistance. Patients and methods We analysed 279 patients consecutively treated with sorafenib for the clinical analysis. Of the 86 (30%) patients with DM2, 52 (19%) were on chronic treatment with metformin and 34 (12%) with insulin. We included 43 patients with HCC for the biological study: 19 (44.1%) were diabetic and 14 (73.7%) of these received metformin for DM2. SIRT-3 expression was investigated by immunohistochemistry (IHC) in formalin-fixed and paraffin-embedded (FFPE) samples. Results In HCC patients undergoing chronic treatment with metformin, the use of sorafenib was associated with poor progression-free survival (PFS) and overall survival (OS) (1.9 and 6.6 months, respectively) compared to 3.7 months and 10.8 months, respectively, for patients without DM2 and 8.4 months and 16.6 months, respectively, for patients on insulin (P <.0001). We also observed that SIRT-3 protein expression was significantly higher in patients treated with metformin than in those not taking this medication (65% versus 25%, respectively) (P =.013). Conclusions Our findings could be attributed to increased tumour aggressiveness and resistance to sorafenib caused by chronic treatment with metformin.

Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale / Casadei Gardini, Andrea; Faloppi, Luca; De Matteis, Serena; Foschi, Francesco Giuseppe; Silvestris, Nicola; Tovoli, Francesco; Palmieri, Vincenzo; Marisi, Giorgia; Brunetti, Oronzo; Vespasiani-Gentilucci, Umberto; Perrone, Giuseppe; Valgiusti, Martina; Granato, Anna Maria; Ercolani, Giorgio; Negrini, Giulia; Tamburini, Emiliano; Aprile, Giuseppe; Passardi, Alessandro; Santini, Daniele; Cascinu, Stefano; Frassineti, Giovanni Luca; Scartozzi, Mario. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 86:(2017), pp. 106-114. [10.1016/j.ejca.2017.09.003]

Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale

Casadei Gardini, Andrea
;
Negrini, Giulia;Cascinu, Stefano;Scartozzi, Mario
2017

Abstract

Purpose In 2015, we published a study on a small series of patients with hepatocellular carcinoma (HCC) treated chronically with metformin for type II diabetes mellitus (DM2) who showed a poorer response to sorafenib. The aim of the present study was to validate the prognostic significance of metformin in HCC patients treated with sorafenib, providing a biological rationale for the mechanism of resistance to sorafenib in patients on chronic metformin therapy, and to clarify the role of sirtuin-3 (SIRT-3), a protein involved in metabolic diseases and acknowledged as a tumour suppressor in HCC, in this resistance. Patients and methods We analysed 279 patients consecutively treated with sorafenib for the clinical analysis. Of the 86 (30%) patients with DM2, 52 (19%) were on chronic treatment with metformin and 34 (12%) with insulin. We included 43 patients with HCC for the biological study: 19 (44.1%) were diabetic and 14 (73.7%) of these received metformin for DM2. SIRT-3 expression was investigated by immunohistochemistry (IHC) in formalin-fixed and paraffin-embedded (FFPE) samples. Results In HCC patients undergoing chronic treatment with metformin, the use of sorafenib was associated with poor progression-free survival (PFS) and overall survival (OS) (1.9 and 6.6 months, respectively) compared to 3.7 months and 10.8 months, respectively, for patients without DM2 and 8.4 months and 16.6 months, respectively, for patients on insulin (P <.0001). We also observed that SIRT-3 protein expression was significantly higher in patients treated with metformin than in those not taking this medication (65% versus 25%, respectively) (P =.013). Conclusions Our findings could be attributed to increased tumour aggressiveness and resistance to sorafenib caused by chronic treatment with metformin.
3-ott-2017
86
106
114
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale / Casadei Gardini, Andrea; Faloppi, Luca; De Matteis, Serena; Foschi, Francesco Giuseppe; Silvestris, Nicola; Tovoli, Francesco; Palmieri, Vincenzo; Marisi, Giorgia; Brunetti, Oronzo; Vespasiani-Gentilucci, Umberto; Perrone, Giuseppe; Valgiusti, Martina; Granato, Anna Maria; Ercolani, Giorgio; Negrini, Giulia; Tamburini, Emiliano; Aprile, Giuseppe; Passardi, Alessandro; Santini, Daniele; Cascinu, Stefano; Frassineti, Giovanni Luca; Scartozzi, Mario. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 86:(2017), pp. 106-114. [10.1016/j.ejca.2017.09.003]
Casadei Gardini, Andrea; Faloppi, Luca; De Matteis, Serena; Foschi, Francesco Giuseppe; Silvestris, Nicola; Tovoli, Francesco; Palmieri, Vincenzo; Marisi, Giorgia; Brunetti, Oronzo; Vespasiani-Gentilucci, Umberto; Perrone, Giuseppe; Valgiusti, Martina; Granato, Anna Maria; Ercolani, Giorgio; Negrini, Giulia; Tamburini, Emiliano; Aprile, Giuseppe; Passardi, Alessandro; Santini, Daniele; Cascinu, Stefano; Frassineti, Giovanni Luca; Scartozzi, Mario
File in questo prodotto:
File Dimensione Formato  
casadeigardini2017.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 802.73 kB
Formato Adobe PDF
802.73 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1177503
Citazioni
  • ???jsp.display-item.citation.pmc??? 34
  • Scopus 56
  • ???jsp.display-item.citation.isi??? 58
social impact